Steven I. Sherman, MD

Steven I. Sherman, MD, associate vice-provost for Clinical Research, professor and chair, Endocrine Neoplasia and Hormonal Disorders, MD Anderson Cancer Center, discusses the relationship between thyroid-stimulating hormone levels and outcomes from the phase III SELECT trial. The SELECT trial looked at lenvatinib versus placebo for the treatment of patients with relapsed/refractory differentiated thyroid cancer.

One side effect of lenvatinib is that it alters the absorption of levothyroxine.

It was anticipated that this effect would raise serum TSH levels. This could be significant because TSH can stimulate the growth of thyroid cancer.

Though many patients developed increased TSH levels and needed increased dosing of thyroid hormone throughout the SELECT trial, the efficacy of lenvatinib was not affected.

Articles

Steven I. Sherman, MD, discusses the relationship between thyroid-stimulating hormone levels and outcomes from the phase III SELECT trial.

Steven I. Sherman, MD | Authors

Articles

The Relationship Between Thyroid-Stimulating Hormone Levels and Outcomes From SELECT